Microsoft and Adaptive Biotechnologies Expand Their Collaboration for Mapping the Immune Response to COVID-19

 Microsoft and Adaptive Biotechnologies Expand Their Collaboration for Mapping the Immune Response to COVID-19

Microsoft and Adaptive Biotechnologies Expand Their Collaboration for Mapping the Immune Response to COVID-19

Shots:

  • The companies collaborate on mapping the immune system’s response to threats, including the COVID-19 threat
  • The focus of the alliance is to study population-wide immune responses to the COVID-19 with their findings to be publicly available via an open data portal. Following the study of immune responses, the companies expected to provide unique insight for new therapies and diagnostics
  • In Apr’2020, Adaptive will begin collecting de-identified blood samples from people diagnosed with COVID-19. Utilizing Adaptive’s technology, researchers will sequence immune cell receptors from the samples and the finding will be analyzed by utilizing Microsoft’s ML and Azure Cloud platform

Click here ­to­ read full press release/ article | Ref: Microsoft | Image: Microsoft

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post